214 related articles for article (PubMed ID: 33851435)
1. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
Skou AS; Juul-Dam KL; Ommen HB; Hasle H
Br J Haematol; 2021 Nov; 195(3):310-327. PubMed ID: 33851435
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; Vålerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
4. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
6. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
7. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
[TBL] [Abstract][Full Text] [Related]
8. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
9. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
10. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
11. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
[TBL] [Abstract][Full Text] [Related]
12. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
[TBL] [Abstract][Full Text] [Related]
13. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS; Loo S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217
[TBL] [Abstract][Full Text] [Related]
14. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
[TBL] [Abstract][Full Text] [Related]
15. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
16. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
17. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia.
Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Banaclocha HM; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
Clin Transl Oncol; 2023 May; 25(5):1446-1454. PubMed ID: 36598635
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
20. Measurable residual disease testing in acute myeloid leukaemia.
Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]